Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Vandetanib
CAS 443913-73-3
Vandetanide is a multi-target tyrosine kinase inhibitor, belonging to anilinoquinozoline compounds, known as "second generation Iressa". It not only acts on EGFR, VEGFR and RET tyrosine kinases of tumor cells, but also inhibits other tyrosine kinases and serine / threonine kinases. Vandetanide is the first approved medulloid thyroid cancer treatment drug, suitable for the treatment of unresectable, locally advanced or metastatic medulloid thyroid cancer with symptoms or progression. In a randomized, placebo-controlled clinical trial, vandetanib significantly delayed the progression of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300mg (oral), and the treatment should be stopped when the patient has tolerance to the drug or cannot tolerate its toxicity. The most common adverse reactions are diarrhea, rash, acne, nausea, hypertension, headache, fatigue, anorexia and abdominal pain.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
